Last reviewed · How we verify
NPO-11
NPO-11 is a small molecule that targets the SGLT2 receptor.
NPO-11 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | NPO-11 |
|---|---|
| Sponsor | Nihon Pharmaceutical Co., Ltd |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, NPO-11 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Study of NPO-11 in Patients Undergoing Gastrointestinal Endoscopy (PHASE3)
- Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy (PHASE3)
- Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy (PHASE3)
- Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (PHASE3)
- Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men (PHASE3)
- Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |